AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir

Pfizer's competitive grants programme posts requests for proposals for independent research, quality improvement, and education initiatives aligned with areas of medical need.

Pfizer lists this opportunity for Eligible independent organisations, Biomedical Sciences, Australia, Canada, China, Germany, Greece, Japan, Korea, and Taiwan. Applicants should use the official call page to confirm final requirements before submitting.

Applicants should be eligible independent organisations able to design, sponsor, implement, and conduct the proposed research in compliance with applicable requirements.

This RFP is listed for Australia, Canada, China, Germany, Greece, Japan, Korea, and Taiwan.

Applicants should review the official RFP PDF for country-specific, organisational, investigator, budget, and submission requirements.

Research on AI-enabled models for timely COVID-19 treatment with nirmatrelvir/ritonavir.

Projects should address eligibility assessment and drug-drug interaction management in ways that can improve timely treatment decision support.

Funding is awarded through Pfizer's competitive grant process according to the RFP, approved budget, and internal review.

Application due date: Application due date: Jul 7, 2026.

Confirm the exact deadline time, time zone, and submission route on the official call page.

Plan internal approvals, partner confirmations, budgets, letters, and portal submission before the final deadline.

Use Pfizer's official competitive grants page, open the RFP for this call, and submit through Pfizer's grant application process by 7 July 2026.

Before submitting, check required documents, eligible costs, attachments, page limits, institutional approvals, and whether the opportunity uses an expression of interest, full proposal, registration, or nomination stage.